Pharmaceutical company Apnimed plans to file for FDA approval of AD109 in early 2026 after the drug met its primary endpoint in a second Phase 3 trial, potentially offering relief to the estimated 30 million Americans who struggle with CPAP machines to treat obstructive sleep apnea.
The medication, branded as LunAIRo, demonstrated a significant reduction in the Apnea-Hypopnea Index from baseline at 26 weeks compared to placebo, with no serious adverse events reported during the trial. If approved, it would become the first oral pharmaceutical treatment for the condition.
A New Era in Sleep Medicine
"We really now are entering precision sleep medicine," said one researcher familiar with the trial data, suggesting that AD109 could herald an era in which some patients completely shed their CPAP devices.
The drug works by addressing what scientists believe is the neuromuscular root cause of upper airway collapse during sleep. AD109 combines aroxybutynin, a novel antimuscarinic compound, with atomoxetine, a selective norepinephrine reuptake inhibitor already approved for treating ADHD.
Unlike CPAP machines, which force air through the airway to keep it open, the oral medication targets the brain signals that control throat muscle tone during sleep. This mechanism could prove particularly valuable for the estimated 50% of sleep apnea patients who abandon CPAP therapy within the first year due to discomfort, noise or claustrophobia.
GLP-1 Drugs Show Unexpected Benefits
In related research, a January 2026 study published in JAMA Network Open found that obese patients with type 2 diabetes are less likely to need CPAP machines if they take GLP-1 medications such as semaglutide (Ozempic) or tirzepatide (Zepbound).
The study found patients taking these popular weight-loss and diabetes drugs were also less likely to die or require hospitalization for sleep apnea-related complications.
A post-hoc analysis of the Phase 3 SURMOUNT-OSA trials showed tirzepatide provided consistent benefits in adults with moderate to severe obstructive sleep apnea and obesity, with significant improvements in AHI scores, sleep apnea-specific hypoxic burden, systolic blood pressure and body weight.
The findings suggest that for patients with both obesity and sleep apnea, treating the underlying weight issue may address multiple health concerns simultaneously.
New Device Technology Offers Another Path
For patients who will continue to need positive airway pressure therapy, new technology may improve the experience. On Dec. 17, 2025, SleepRes received FDA 510(k) clearance for its Kricket PAP device, which uses a technology called KPAP.
Unlike traditional CPAP machines that maintain constant, fixed pressure throughout the night, Kricket dynamically adapts pressure delivery throughout the breathing cycle. The company plans to launch the device in the first half of 2026.
Growing Prevalence Drives Urgency
The push for new treatments comes as researchers project significant growth in sleep apnea cases. A major modeling study published in The Lancet Respiratory Medicine estimates that by 2050, nearly 77 million U.S. adults will be living with obstructive sleep apnea, a projected 35% increase from 2020.
The study noted a particularly sharp rise expected among women, who have historically been underdiagnosed for the condition.
Lifestyle Changes Still Matter
While pharmaceutical and device innovations advance, research presented at the Clinical Trials on Alzheimer's Disease conference highlighted the value of behavioral interventions. The POINTER-zzz study found that older adults who followed a structured health-related intervention experienced improved sleep apnea outcomes.
"This is the first study ever to assess the effects of lifestyle intervention in a randomized controlled trial on objective measures of sleep in older adults at risk for dementia," the researchers noted.
The intervention reduced harmful respiratory events during sleep by one to two events per hour, translating to roughly 10 fewer clinically significant respiratory events per night.
For the millions of Americans who dread strapping on their CPAP masks each night, these developments offer hope that effective alternatives may soon be available. Whether through pills, injections, improved devices or lifestyle changes, the treatment landscape for sleep apnea is evolving rapidly.
